547-96-6

Basic information

• Product Name: 3,7,12-trihydroxycoprostane
• Synonyms: 3,7,12-trihydroxycoprostane;3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestane;3alpha,7alpha,12alpha-Trihydroxycoprostane;5beta-Cholestane-3alpha,7alpha,12alpha-triol;C05454;Trihydroxycoprostane;(3α,5β,7α,12α)-Cholestane-3,7,12-triol
• CAS NO: 547-96-6
• Molecular Formula: C27H48O3
• Molecular Weight: 420.67
• Product Categories: Enzyme substrates;Steroids
• Mol File: 547-96-6.mol
• Article Data: 2

Chemical Properties

• Melting Point: 180-181°C
• Boiling Point: 535.5°C at 760 mmHg
• Flash Point: 222.8°C
• Appearance: /
• Density: 1.051g/cm³
• Vapor Pressure: 1.06E-13mmHg at 25°C
• Refractive Index: 1.529
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly, Sonicated)
• PKA: 14.65±0.70(Predicted)
• CAS DataBase Reference: 3,7,12-trihydroxycoprostane(CAS DataBase Reference)
• NIST Chemistry Reference: 3,7,12-trihydroxycoprostane(547-96-6)
• EPA Substance Registry System: 3,7,12-trihydroxycoprostane(547-96-6)

Safety Data

• Hazardous Substances Data: 547-96-6(Hazardous Substances Data)

Usage

Description

3,7,12-Trihydroxycoprostane is a sterol compound that is structurally similar to cholesterol. It serves as a substrate for the sterol 27-hydroxylase enzyme, which plays a crucial role in the bile salt synthetic pathway. The presence of this compound in urine can be indicative of certain health conditions, such as jaundice or, in more severe cases, Xanthomatosis.

Uses

Used in Medical Diagnostics:
3,7,12-Trihydroxycoprostane is used as a biomarker for the detection and monitoring of liver function and bile salt synthesis. Its accumulation in urine can indicate the presence of jaundice or Xanthomatosis, aiding in the diagnosis and treatment of these conditions.
Used in Pharmaceutical Research:
As a substrate for the sterol 27-hydroxylase enzyme, 3,7,12-trihydroxycoprostane is utilized in pharmaceutical research to study the mechanisms of bile salt synthesis and its regulation. This knowledge can contribute to the development of new therapeutic agents for liver-related disorders and other conditions influenced by bile salt metabolism.

InChI:InChI=1/C27H48O3/c1-16(2)7-6-8-17(3)20-9-10-21-25-22(15-24(30)27(20,21)5)26(4)12-11-19(28)13-18(26)14-23(25)29/h16-25,28-30H,6-15H2,1-5H3/t17-,18+,19-,20-,21+,22+,23-,24+,25+,26+,27-/m1/s1

Upstream product

• 503-74-2 3-methylbutyric acid 
• 81-25-4 cholic acid 
• 97925-10-5 3α,7α,12α-trihydroxy-5β-cholestan-24-one 

Downstream Products

• 547-97-7 7α,12α-dihydroxy-5β-cholestan-3-one 

Relevant articles and documents

Facial amphiphiles and methods of use

The invention provides amphiphilic compounds with hydrophobic and hydrophilic faces. The compounds can be readily prepared from steroids such as cholic acid or deoxycholic acid, which provide hydrophobic skeletons with structures similar to that of the li